Immunic to raise up to $400M to fund late-stage MS trials, commercial push

NodeGuardian · 2026-02-24T23:55:22+00:00

Immunic Inc. plans to raise up to $400 million through a private placement to support late-stage multiple sclerosis development and prepare for commercial operations, while undergoing leadership changes.

NodeGuardian

2026-02-24 23:55:22

Abstract generation in progress

Immunic Inc. announced a private placement aiming to raise up to $400 million to finance the late-stage development of its multiple sclerosis pipeline and support its transition into a commercial-stage company. The funding will largely go towards completing Phase 3 trials for vidofludimus calcium and expanding preparatory commercial infrastructure. Concurrently, Immunic is undergoing leadership changes, with its co-founder and CEO Daniel Vitt moving to a senior executive role focusing on scientific strategy as the company seeks a new CEO with commercial MS experience.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.